IGC Pharma Adds Visionary Investigators Network as Clinical Site to Phase 2 CALMA Trial February 23, 2026 Read More »
IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment May 19, 2026 Read More »
IGC Pharma to Present Tau-PET Biomarker Research at 2026 Global Tau Conference May 15, 2026 Read More »
